ARTICLE | Company News
Memory Pharmaceuticals, Bayer deal
September 17, 2001 7:00 AM UTC
Memory obtained exclusive worldwide rights from BAYG to MEM 1003, a neuronal calcium channel modulator, to treat dementia. Memory will pay BAYG upfront fees, milestones and royalties. ...